Screen for Complications

Print Friendly, PDF & Email

Top tips:

  1. In all patients with compensated cirrhosis, assess whether the patient has clinically significant portal hypertension. If they do and there are no contraindications, consider starting carvedilol (or a non-selective beta-blocker) to reduce the risk of decompensation.
  2.  In those patients with compensated cirrhosis who are not already on carvedilol or a non-selective beta-blocker, a fibroscan score of >20 kPA OR a platelet count of <150,000 tells you the patient should be considered for endoscopy. If the fibroscan score is <20 kPA AND platelet count is >150,000 OR the patient is on carvedilol or a non-selective beta-blocker, screening endoscopy is not needed.
  3. Patients with cirrhosis should undergo HCC surveillance with ultrasound and AFP every six months (notably, although by guidelines the AFP is optional, in our experience this is suggested)
  4. Patients who have had a diagnosis of cirrhosis at anytime (regardless of whether they have improved or even cleared their Hepatitis B or C) should continue to undergo HCC surveillance
Dr. Ramji cartoon
Dr. fung cartoon
Dr. Burak cartoon

Thank you to Dr. Ramji, Dr. Fung, and Dr. Burak for your efforts creating the content on this page. Check out the bottom of the page for a short video from Dr. Fung!

Screening for liver related complications

Compensated cirrhosis

Defined by: the absence of ascites, hepatic encephalopathy, variceal bleeding or jaundice (see more info)

Decompensated cirrhosis

Defined by: the presence of ascites, hepatic encephalopathy, variceal bleeding or jaundice (see more info)

Introducing Dr. Ramji, Dr. Fung and Dr. Burak

Video 1 - Automating HCC surveillance - information about automatic recall ultrasound surveillance recall programs in Calgary and Edmonton.

Patient materials:

You can direct patients to the following:

HCC

Liver biopsy

Lab tests

Downloadable content:

You can download these to print or view offline:

Baveno guidelines 2021

AASLD Guidance 2018

EASL Clinical Practice Guidelines

References:

This section was adapted from content using the following evidence based resources in combination with expert consensus. The presented information is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care.

Authors: Michelle Carbonneau NP, Dr. Alnoor Ramji, Dr. Puneeta Tandon

References:

  1. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018 Aug;69(2):406-460 PMID 29653741
  2. de Franchis, R., Bosch, J., Garcia-Tsao, G., Reiberger, T., Ripoll, C., & Baveno VII Faculty (2022). Baveno VII – Renewing consensus in portal hypertension. Journal of hepatology76(4), 959–974. https://doi.org/10.1016/j.jhep.2021.12.022 PMID 35120736
  3. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018 Jul;69(1):182-236 PMID 29628281
  4. Loomba R et al. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology 2020 Jan 29 PMID 32006545
guest

We would really appreciate your feedback to make this page better. Thanks for taking the time to do this!

How would you best describe yourself?
I found this webpage useful
The content on this page is easy to navigate
I found what I was looking for on the page
0 Comments
Inline Feedbacks
View all comments